Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
Amarin Corporation has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company maintained an average closing share price of at least $1.00 over 10 consecutive business days ending April 28, 2025, meeting Rule 5550(a)(2) requirements.
The announcement came on April 29, 2025, with confirmation from Nasdaq's Listing Qualifications Department that the matter is now closed. This development follows Amarin's ADS ratio change, which was implemented to secure the company's public listing.
CEO Aaron Berg emphasized this as an important milestone, stating that with the listing compliance secured, Amarin will continue focusing on maximizing the global value of their product VASCEPA/VAZKEPA for patient benefit. The company is now in full compliance with all Nasdaq listing requirements and will maintain its trading status on the exchange.
Amarin Corporation ha riconquistato con successo la conformità al requisito minimo del prezzo di offerta di Nasdaq, garantendo così la sua permanenza nel Nasdaq Capital Market. L'azienda ha mantenuto un prezzo medio di chiusura per azione di almeno 1,00 dollaro per 10 giorni lavorativi consecutivi terminati il 28 aprile 2025, rispettando i requisiti della Regola 5550(a)(2).
L'annuncio è stato fatto il 29 aprile 2025, con la conferma da parte del Dipartimento di Qualifica delle Società di Nasdaq che la questione è ora chiusa. Questo sviluppo segue la modifica del rapporto ADS di Amarin, attuata per assicurare la quotazione pubblica della società.
Il CEO Aaron Berg ha sottolineato che si tratta di un traguardo importante, affermando che, una volta garantita la conformità alla quotazione, Amarin continuerà a concentrarsi sul massimizzare il valore globale del loro prodotto VASCEPA/VAZKEPA a beneficio dei pazienti. L'azienda è ora pienamente conforme a tutti i requisiti di quotazione Nasdaq e manterrà il suo status di negoziazione sull'exchange.
Amarin Corporation ha recuperado con éxito el cumplimiento del requisito mínimo del precio de oferta de Nasdaq, asegurando su continuidad en el Nasdaq Capital Market. La compañía mantuvo un precio medio de cierre de al menos 1,00 USD durante 10 días hábiles consecutivos hasta el 28 de abril de 2025, cumpliendo con los requisitos de la Regla 5550(a)(2).
El anuncio se realizó el 29 de abril de 2025, con la confirmación del Departamento de Calificaciones de Listado de Nasdaq de que el asunto está cerrado. Este desarrollo sigue al cambio en la proporción de ADS de Amarin, implementado para asegurar la cotización pública de la empresa.
El CEO Aaron Berg destacó que este es un hito importante, afirmando que, con el cumplimiento de la cotización asegurado, Amarin continuará enfocándose en maximizar el valor global de su producto VASCEPA/VAZKEPA para el beneficio de los pacientes. La empresa ahora cumple plenamente con todos los requisitos de listado de Nasdaq y mantendrá su estatus de negociación en la bolsa.
아마린 코퍼레이션이 나스닥의 최소 입찰 가격 요건을 성공적으로 충족하여 나스닥 캐피탈 마켓 상장 자격을 유지하게 되었습니다. 회사는 2025년 4월 28일까지 연속 10거래일 동안 평균 종가가 최소 $1.00 이상을 유지하여 규칙 5550(a)(2) 요건을 충족했습니다.
이 발표는 2025년 4월 29일 나스닥 상장 자격 부서로부터 이 문제가 해결되었음을 확인받으며 이루어졌습니다. 이번 조치는 회사의 공개 상장을 확보하기 위해 시행된 아마린의 ADS 비율 변경에 따른 것입니다.
CEO 아론 버그는 이를 중요한 이정표로 강조하며, 상장 요건을 충족함에 따라 아마린은 환자 이익을 위해 제품 VASCEPA/VAZKEPA의 글로벌 가치를 극대화하는 데 계속 집중할 것이라고 밝혔습니다. 회사는 현재 나스닥 상장 요건을 모두 충족하여 거래 상태를 유지할 것입니다.
Amarin Corporation a réussi à se conformer à nouveau à l'exigence minimale du prix d'offre de Nasdaq, assurant ainsi le maintien de sa cotation sur le Nasdaq Capital Market. La société a maintenu un cours de clôture moyen d'au moins 1,00 $ sur 10 jours ouvrables consécutifs se terminant le 28 avril 2025, respectant ainsi les exigences de la règle 5550(a)(2).
L'annonce a été faite le 29 avril 2025, avec la confirmation du Département des qualifications de cotation de Nasdaq que l'affaire est désormais close. Ce développement fait suite au changement du ratio ADS d'Amarin, mis en œuvre pour garantir la cotation publique de l'entreprise.
Le PDG Aaron Berg a souligné qu'il s'agit d'une étape importante, déclarant qu'avec la conformité à la cotation assurée, Amarin continuera à se concentrer sur la maximisation de la valeur mondiale de leur produit VASCEPA/VAZKEPA au bénéfice des patients. La société est désormais en pleine conformité avec toutes les exigences de cotation de Nasdaq et maintiendra son statut de négociation sur la bourse.
Amarin Corporation hat erfolgreich die Einhaltung der Mindestgebotspreis-Anforderung der Nasdaq wiedererlangt und sichert damit die Fortsetzung der Notierung am Nasdaq Capital Market. Das Unternehmen hielt einen durchschnittlichen Schlusskurs von mindestens 1,00 USD über 10 aufeinanderfolgende Handelstage bis zum 28. April 2025 ein und erfüllte damit die Anforderungen der Regel 5550(a)(2).
Die Bekanntgabe erfolgte am 29. April 2025 mit der Bestätigung der Nasdaq-Listing-Qualifikationsabteilung, dass die Angelegenheit nun abgeschlossen ist. Diese Entwicklung folgt auf die Änderung des ADS-Verhältnisses von Amarin, die umgesetzt wurde, um die öffentliche Notierung des Unternehmens zu sichern.
CEO Aaron Berg betonte, dass dies ein wichtiger Meilenstein sei, und erklärte, dass Amarin sich nach Sicherstellung der Listing-Konformität weiterhin darauf konzentrieren werde, den globalen Wert ihres Produkts VASCEPA/VAZKEPA zum Nutzen der Patienten zu maximieren. Das Unternehmen erfüllt nun alle Nasdaq-Listing-Anforderungen vollständig und wird seinen Handelsstatus an der Börse beibehalten.
- Regained Nasdaq listing compliance by meeting minimum bid price requirement
- Secured continued public listing on Nasdaq Capital Market
- Company now in full compliance with all Nasdaq listing requirements
- Required ADS ratio change to maintain listing, indicating previous share price weakness
Insights
Amarin preserves critical Nasdaq listing through ADS ratio change, maintaining market access and avoiding the negative consequences of delisting.
Amarin's regained compliance with Nasdaq's minimum share price requirement represents a significant regulatory milestone for the company. After implementing an ADS ratio change (effectively a mechanism to adjust share price), Amarin successfully maintained the required
This compliance achievement provides critical structural benefits that many investors might overlook. Maintaining Nasdaq listing ensures continued access to liquid trading markets, visibility to institutional investors, and preserves the company's ability to raise capital efficiently if needed. Had delisting occurred, Amarin would have faced restricted market access, potential forced selling by institutions with exchange-listing mandates, and diminished ability to attract new investors.
While the ADS ratio change was a technical necessity rather than a reflection of fundamental business improvement, it demonstrates management's commitment to maintaining market structure integrity. The company can now return focus to its stated priority of maximizing the global value of VASCEPA/VAZKEPA without the distraction of listing compliance issues.
This regulatory clearance provides Amarin with improved operational stability from a market structure perspective, creating a more secure foundation for the company's continued commercialization efforts.
Nasdaq compliance secures Amarin's public market presence, essential for continued commercialization and maximizing VASCEPA/VAZKEPA's global potential.
Amarin's successful resolution of its Nasdaq listing challenge represents an important stabilizing development for its commercialization infrastructure. The company's ability to maintain public listing status through an ADS ratio change provides the market structure necessary to support its global commercialization strategy for VASCEPA/VAZKEPA.
The significance extends beyond regulatory compliance—public market access is essential infrastructure for biopharmaceutical commercialization efforts. Continued Nasdaq listing ensures Amarin can maintain visibility with institutional healthcare investors, access capital markets efficiently if additional funding becomes necessary for commercial expansion, and maintain liquidity for existing shareholders.
CEO Aaron Berg's statement directly connects this compliance achievement to the company's mission of "maximizing the value of VASCEPA/VAZKEPA globally for the millions of patients who can benefit from it," highlighting management's understanding that market structure directly impacts commercial capabilities.
For a commercial-stage biopharmaceutical company like Amarin, maintaining exchange listing provides stability for both internal operations and external partnerships that are critical to global commercialization efforts. With this compliance matter resolved, the company can fully redirect resources toward its core mission of expanding market access for its cardiovascular therapy.
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing --
-- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA –
DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications.
On April 29, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of April 28, 2025 the Company’s common stock had maintained an average closing share price of at least
Amarin is now in full compliance with all Nasdaq listing requirements and will continue to be listed and traded on Nasdaq.
“Today’s announcement is an important step for the Company by maintaining our public listing on the Nasdaq Capital Market,” said Aaron Berg, President & CEO, Amarin. “With this matter now behind us, we will continue our focus on maximizing the value of VASCEPA/VAZKEPA globally for the millions of patients who can benefit from it.”
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on the beliefs and assumptions and information currently available to Amarin. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the fiscal year ended 2024.
Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor & Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
Investor.relations@amarincorp.com
FAQ
How did Amarin (AMRN) regain Nasdaq compliance in April 2025?
What impact does Nasdaq compliance have on Amarin (AMRN) stock listing?
What steps did Amarin take to meet Nasdaq's minimum bid price requirement?
What is Amarin's strategy following Nasdaq compliance in 2025?
When did Amarin (AMRN) receive official Nasdaq compliance confirmation?
